181 results about "Quinoxaline" patented technology

The invention relates to 3-quinoxalinyl imidazoline thioketone derivatives, a synthesis method and application technical contents. The structural general formula of the derivative is formula 1 or formula 2. The invention provides a preparation method of the derivative. The invention proves that the developed 3-quinoxalinyl imidazoline thioketone derivative has an anti-myocardial hypertrophy effect and can be applied to preparation, research and development of anti-myocardial hypertrophy drugs.

An organometallic complex having an emission peak in a long wavelength region (a visible region having a wavelength of 700 nm or greater or a near-infrared region) is provided. The organometallic complex has a structure represented by General Formula (G1), in which a ligand having a quinoxaline skeleton is coordinated to a central metal, and an electron-withdrawing group (e.g., fluorine, a cyano group, a trifluoromethyl group, a trifluoromethylsulfonyl group, or a pentafluorosulfanyl group) is included as a substituent at at least one substitutable position of the benzene ring of the quinoxaline skeleton of the ligand.

The application belongs to the field of compound synthesis and particularly relates to a photocatalytic preparation method of quinoxaline-2,3-dione compounds, which comprises the following steps: preparing a raw material solution containing quinoxaline-2-ketone, mercaptan, a photocatalyst and acetonitrile, and performing a photocatalytic reaction under light to obtain a quinoxaline-2,3-dione compound product; the mercaptan is C1-C4 alkyl mercaptan, and the -SH is connected to a primary carbon or a secondary carbon. The application adopts a photocatalytic method to perform hydroxylation on the C3 position of quinoxaline-2-ketone, and further controls the combination of the mercaptan and acetonitrile solvent to improve the photocatalytic reaction effect of C3 hydroxylation.

The present invention discloses an efficient C-H arylation reaction between quinoxalinone compounds and aryltriazenes induced by ionic liquids. Specifically, it relates to a method for the electrochemical synthesis of 3-arylquinoxalinone compounds, using aryltriazenes as stable arylation reagents and ionic liquids as promoters and electrolytes. Under mild, metal-free, and oxidant-free conditions, the method can synthesize a variety of 3-arylquinoxalinone compounds and arylated quinoxaline compounds in moderate to excellent yields. This scheme has the remarkable characteristics of simple operation, excellent functional group tolerance, high selectivity, strong product derivatization, and suitability for gram-scale continuous flow chemical synthesis.

The application discloses a preparation method of a diphenylmethyl quinoxaline ketone derivative, and belongs to the technical field of biological medicines. The structure of the diphenylmethyl quinoxaline ketone derivative is shown in the specification. The application adopts a cross dehydrogenative coupling strategy, realizes quinoxaline ketone 3-alkylation through direct activation of an alkane and accompanying hydrogen atom transfer, and has the advantages of mild reaction conditions, cheap and easily available reagents, and higher efficiency and environmental friendliness. The diphenylmethyl quinoxaline ketone derivative has high-efficiency and broad-spectrum antifungal activity, shows inhibitory effects on a plurality of common plant pathogenic fungi, and can be developed into a product for treating plant fungal infections.

The invention belongs to the technical field of organic solar cell materials, and relates to a benzodithiophene polymer donor with a simple and stable structure and a preparation method and application thereof. The invention discloses a benzodithiophene polymer donor PBTQ-X (F / Cl / 2F) with a simple and stable structure, and discloses a preparation method of the benzodithiophene polymer donor PBTQ-X (F / Cl / 2F), and the preparation method comprises the following steps: under the action of a Stille coupling catalyst, carrying out two-stage polymerization on benzodithiophene containing bis (trimethyltin) and a quinoxaline derivative containing a dibromothiophene pi bridge, carrying out two-stage heating reflux reaction, and carrying out post-treatment to obtain the benzodithiophene polymer donor PBTQ-X (F / Cl / 2F). Adding an end-capping reagent for end capping; and finally, settling after passing through methanol, thereby obtaining the product. The benzodithiophene polymer donor with a simple and stable structure can be applied to an active layer of an organic solar cell device, and shows relatively good photovoltaic performance and long-term stability.

This invention discloses a polysubstituted indole[1,2-a]quinoxaline compound, its preparation method, and its applications. The structural formula of the polysubstituted indole[1,2-a]quinoxaline compound of this invention is or , where R 1 Selected from -H or -F, R 2 The compounds are selected from phenyl, 4-methylphenyl, 4-methoxyphenyl, or 4-fluorophenyl. The polysubstituted indole[1,2-a]quinoxaline compounds of this invention have novel structures and significant antitumor activity, making them suitable for the synthesis of anticancer drugs. Furthermore, their preparation methods offer advantages such as readily available and inexpensive catalysts, broad substrate applicability, good functional group tolerance, simple operation, mild reaction conditions, and high step economy, making them suitable for large-scale industrial production and application.

The present invention relates to novel heteroaryl-substituted (aza)quinoxaline derivatives of the general formula (I), in which the structural elements A1, A2, A3, A4, R1, R2, R3, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.

The invention discloses a near-infrared two-region aggregation-induced emission I-type photosensitizer as well as preparation and application thereof. The chemical structural general formula of the near-infrared two-region aggregation-induced emission I-type photosensitizer is shown in the specification, wherein X is independently selected from one of O, S and Se, R1 is independently selected from one of straight-chain alkyl groups with the carbon atom number of 1-20, R2 is independently selected from one of-F,-CN,-CF3,-OCH3,-C4H9 and-CH3, and R3 is independently selected from one of-H,-Br,-I and-TPA. A D-pi-A-pi-D type near-infrared two-region aggregation-induced emission I type photosensitizer is designed and synthesized, and 4, 4 '-dimethoxydiphenylamine is used as a distortion donor unit, ortho-substituted hexylthiophene is used as a pi-bridge, and acenaphthene alkene thiadiazolo quinoxaline and other derivatives are used as central acceptor units. The near-infrared two-region aggregation-induced emission type I photosensitizer has good fluorescence and active oxygen generation and photothermal conversion capabilities, and can be used for cancer multi-mode diagnosis and treatment integrated research.

A combination for use in treating cancer is provided. The combination comprises a therapeutically effective amount of an inhibitor of nuclear import protein Karyopherin Beta 1 (Kpnβ1) such as the substituted pyrrolo[2,3-b]quinoxalines of Formula I and a therapeutically effective amount of an inhibitor of nuclear export protein Chromosome Maintenance 1 (Crm1) such as the hydrazide- containing compounds of Formula II. The combination therapy provides an enhanced anti-cancer therapeutic effect compared to the effect of each of the nuclear transport inhibitors administered alone.

The application provides an organic negative electrode and a metal-air battery, the organic negative electrode comprises an organic matter with a low redox potential, the organic matter with the low redox potential comprises phenazine, diquinoxaline phenazine, a nitrogen heterocyclic ring, a carboxylate or an azo compound, the organic matter in the organic negative electrode is corrosion resistant and the redox potential can be adjusted, even reaching a negative reduction potential comparable to that of hydrogen, so that the phenomenon of hydrogen evolution corrosion cannot occur; a large number of functional groups and active sites in the organic matter can induce uniform deposition of metal ions, and there is no condition for dendrite growth and formation of a passivation layer, so that various problems caused by the above metal negative electrode can be completely avoided; the metal-air battery with the above organic negative electrode has the advantages of long cycle time, stable performance, safety, environmental protection and low cost, and has a wide application prospect in the field of large-scale energy storage.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a quinoxaline compound as well as a preparation method and application thereof. Specifically, the quinoxaline compound provided by the invention is screened by adopting virtual screening and pharmacophore modes, is novel in structure, has relatively good inhibitory activity on MELK, and solves the problem of insufficient development of an existing MELK inhibitor that the activity is not ideal enough, the chemical structure is not diversified enough and the like.

The application discloses a kind of all-organic aqueous zinc ion battery positive electrode materials and preparation method and application, belong to new energy materials and battery technical field, and positive electrode material is nitrogen heterocyclic organic 5,5,12,12'-tetrahydro-2,2'-bi quinoxaline [2,3-b] quinoxaline, negative electrode material is imine and carbonyl organic matter.Nitrogen heterocyclic organic positive electrode loses electron and is oxidized in charging process, and imine and carbonyl organic negative electrode obtains electron and is reduced, so stable charge-discharge cycle can be carried out.The application uses the above-mentioned one all-organic aqueous zinc ion battery positive electrode material and preparation method and application, using structure adjustable and element rich organic positive electrode, relatively stable imine and carbonyl organic negative electrode, environment-friendly and safe water-based electrolyte, can realize the stable charge-discharge of all-organic aqueous zinc ion battery.

The invention relates to the technical field of proton batteries, and discloses a holosymmetric organic sub-battery and a preparation method thereof. The holosymmetric organic sub-battery comprises a positive electrode, a negative electrode, a diaphragm and an electrolyte, the positive electrode is an organic electrode which is subjected to complete discharge treatment, and the negative electrode is an organic electrode which is not subjected to discharge treatment; the organic electrode comprises a current collector and an active material, wherein the active material is a vinyl covalent organic framework material; the electrolyte is an aqueous solution of zinc salt. 2, 3, 7, 8-tetramethylpyrazino [2, 3-g] quinoxaline and a symmetric monomer containing an aldehyde group are subjected to polycondensation and purification through melt polymerization to obtain the vinyl covalent organic framework material, and the vinyl covalent organic framework material has a unique two-step proton redox behavior. The material is used as an active substance for the holosymmetric organic sub-battery, and the specific capacity and the cycle performance of the holosymmetric organic sub-battery are improved by utilizing the unique two-step proton embedding and removing behaviors of the material.

This invention provides a method for preparing 4,1-disubstituted pyrrolo[1,2-a]quinoxaline-1-yl ketone derivatives, belonging to the field of organic synthesis technology. This invention uses 2-(1H-pyrrolo-1-yl)aniline compounds and α-carbonyl acids as reactants, employing only ammonium persulfate as an oxidant. Under metal-free catalysis, a one-pot tandem reaction is carried out to simultaneously complete the cyclization of the pyrrolo[1,2-a]quinoxaline nucleus and the C-1 acylation modification. The substituents at the 4- and 1-positions of the product can be flexibly controlled by changing the α-carbonyl acid with different structures. This method requires no pre-modified substrate, eliminates the need for metal catalysts, avoids the risk of metal residue, and features simplified steps and high functional group compatibility, providing a new green and low-cost route for the synthesis of polysubstituted pyrrolo[1,2-a]quinoxaline ketone derivatives.

The application discloses a synthesis method of C3-substituted quinoxaline ketone derivatives and application thereof. A series of C3-substituted quinoxaline ketone derivatives with both terpene and quinoxaline ketone biological activity skeletons are obtained by using N-alkoxy phthalimide and quinoxaline ketone as starting substrates, under the catalysis of a photocatalyst and visible light irradiation, and at a temperature of 55-65 DEG C for 10-15 h. The application has the advantages of stable and easy-to-prepare raw materials, mild reaction conditions, simple experimental operation, good chemical selectivity and functional group tolerance, and is a green chemical synthesis method with good application prospect. The activity experiment results show that the synthesized C3-substituted quinoxaline ketone derivatives have good inhibiting effect on the growth of plant pathogenic fungi.

The present invention addresses the problem of providing a light-emitting element having excellent luminous efficiency and a highly durable lifespan.　This compound is represented by general formula (1). (In general formula (1), L is a substituted or unsubstituted arylene group or a substituted or unsubstituted heteroarylene group. However, when these groups are substituted, the substituent groups are alkyl groups or alkoxy groups. n is an integer of 2-5. In addition, at least one of the n Ls has a structure represented by general formula (2). A is a substituted or unsubstituted pyrimidyl group, a substituted or unsubstituted triazinyl group, a substituted or unsubstituted quinoxalinyl group, or a substituted or unsubstituted quinazolinyl group. However, when these groups have substituents, the substituents do not form a ring structure. B is a hydrogen atom, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group.) (In general formula (2), R1-R4 are each independently a hydrogen atom, an alkyl or an alkoxy group, and R1-R4 do not bond to each other to form a ring. * represents a bonding position with an adjacent substituent.)

The invention relates to quinoxaline derivatives as anti-cancer drugs. Specifically, the invention relates to azaquinolone compounds of formula (I) and their use in medicine.

The invention relates to a quinoxaline derivative containing trimethyl and n-propyl as well as a preparation method and application of the quinoxaline derivative, and the derivative is 1, 6, 7-trimethyl-3-propyl quinoxaline-2 (1H)-ketone and is particularly suitable for inhibiting fusarium oxysporum. The derivative is prepared by an organic synthesis method which comprises the step of carrying out cyclization reaction on N-protected o-phenylenediamine and a carbonyl compound in the presence of trifluoroacetic acid. Experiments show that the compound has a remarkable antibacterial effect on fusarium oxysporum, and the minimum inhibitory concentration is 0.50 mg / mL. The derivatives can destroy the cell membrane structure of fusarium oxysporum and cause leakage of RNA, protein and reducing sugar in cells, so that the growth of thalli is inhibited. The invention provides a theoretical basis and an experimental basis for developing a novel efficient and low-toxicity bacteriostatic agent.

The present application provides an organic material composition and its application, the organic material composition includes the fused heterocyclic compound containing quinoline structure and hole transport type compound, the fused heterocyclic compound containing quinoline structure has the structure as shown in formula (1), the hole transport type compound has the structure as shown in formula (2).The composition of the present application makes the organic electroluminescent device have lower driving voltage (3.85 V or less), higher current efficiency (25 Cd / A or more) and longer life (267 h or more).

The application discloses a compound shown in formula I. The compound shown in formula I is a 3,5-dimethoxyaniline FGFR2 macrocycle inhibitor. The compound of the application can effectively inhibit the growth of various tumor cells and has FGFR2 inhibiting effect, and thus can be used for preparing an antitumor drug. The application further relates to the compound shown in formula I, a pharmaceutical composition containing the compound shown in formula I and the use of the compound in treating FGFR2-mediated related diseases and preparing a drug for treating FGFR2-mediated related diseases.

The application discloses a method for photocatalytically preparing 3-aminoquinoxalin-2(1 H )-ketone compounds, and belongs to the field of organic synthesis. The application comprises the following steps: quinoxalin-2(1 H )-ketone compounds, fatty amine compounds, a photocatalyst mpg-C3N4 (mesoporous graphite phase carbon nitride) and an alkali DABCO (1,4-diazabicyclo (2.2.2) octane) are added into an organic solvent and uniformly mixed; the reaction is carried out under the irradiation of light in an oxygen atmosphere; and after the reaction is completed, the 3-aminoquinoxalin-2(1 H )-ketone product is obtained through treatment and separation. The application uses DABCO as an alkali and an electron transfer agent, and adopts mpg-C3N4 to photocatalytically prepare 3-aminoquinoxalin-2(1 H )-ketone compounds under the auxiliary condition of DABCO, and it is concluded from DABCO quenching experiments and cyclic voltammetry experiments that there is a single electron transfer relationship between them; and the application has the advantages of mild reaction conditions, simple operation and the ability to synthesize 3-aminoquinoxalin-2(1 H )-ketone compounds in one step.

The patent application discloses an orange-red light thermal activation delayed fluorescence material and a preparation method and application thereof, and relates to the field of organic luminescent materials. The thermal activation delayed fluorescence orange-red light material is composed of an electron acceptor fragment and two same electron donor fragments (triphenylamine), the electron acceptor fragment is quinoxaline-6,7-dicyanide, and the electron donor fragment is triphenylamine. The material has the thermal activation delayed fluorescence characteristic, and the maximum external quantum efficiency of the prepared device is 23.2%.

The invention relates to quinoxaline derivatives as anti-cancer drugs. Specifically, the invention relates to azaquinolone compounds of formula (I) and their use in medicine.

The invention relates to the technical field of organic synthesis, in particular to a preparation method of a 6-sulfonyl tetrahydroquinoxaline compound. The preparation method of the 6-sulfonyl tetrahydroquinoxaline compound comprises the following steps: adding a sodium benzenesulfinate compound, tetrahydroquinoxaline or a derivative thereof and a nitrogen-doped carbon material heterogeneous catalyst into an organic solvent, and reacting under oxygen; the prepared 6-sulfonyl tetrahydroquinoxaline compound is novel in structure, the preparation method has the advantages that operation is simple, raw materials are easy to obtain, substrate compatibility is good, reaction conditions are mild, the catalyst can be recycled and the like, and the 6-sulfonyl tetrahydroquinoxaline compound can be applied to the fields of medicine, pesticide, material science and the like. The method provides a new thought for efficient synthesis of the 6-sulfonyl tetrahydroquinoxaline compound, and is suitable for expanded industrial production.

The invention belongs to the technical field of biomedical detection, and relates to a quinoxaline-derived Aza-BODIPY AIE fluorescent probe, the probe is composed of three parts of fluorophore Aza-BODIPY, rotor benzothiazole and lysosome targeted morpholine, the Aza-BODIPY and benzothiazole are connected through a-C = N-C-group, and the probe is a quinoxaline-derived Aza-BODIPY-AIE fluorescent probe. A precursor intermediate probe 1 is formed by connecting a fluorophore Aza-BODIPY and a rotor benzothiazole through a-C-C = N-group. The invention further discloses a synthesis method of the fluorescent probe and application of the fluorescent probe to lysosome viscosity detection. The probe system disclosed by the invention has significantly increased Stokes shift, and effectively avoids overlapping of excitation / emission spectrums; the fluorescent probe shows typical aggregation-induced emission (AIE) characteristics, and fluorescence enhancement is most remarkable under the condition that the water content is 40-50%; the fluorescent probe has wide-range viscosity response capability (2-610cP), 24 times of fluorescence enhancement can be generated at most, and the detection limit is as low as 0.27 cP; the lysosome co-localization performance is excellent, and the cell compatibility is good; the high-contrast real-time imaging monitoring on the viscosity of the living cell lysosome can be realized.

To provide a new compound useful for treatment, prevention and / or diagnosis of seizure or the like in diseases accompanied by epileptic seizure or convulsive seizure (including multidrug-resistant seizure, intractable seizure, acute symptomatic seizure, febrile seizure and status epilepticus).SOLUTION: There are provided a compound represented by formula [I] and a salt thereof. Ring C is selected from pyridazine, pyrimidine, indole, pyrrolopyridine, indazole, pyrazolopyridine, imidazopyridine, imidazopyrazine, imidazopyridazine, triazolopyridine, pyrazolopyrimidine, imidazopyrimidine, triazolopyrimidine, isoquinoline, naphthyridine, quinazoline, quinoxaline, benzodioxole, oxazine, oxazepine, benzothiazole, and triazolopyridazine, with the proviso that pyrimidine-2, 4-dione and dihydropyrimidine-2, 4-dione are excluded.SELECTED DRAWING: None

This invention discloses a method for synthesizing chiral quinoxalones. Using a copper salt, a chiral ligand, and a base as a catalytic system, the target chiral quinoxalone compound is obtained by reaction in an organic solvent. This invention utilizes an economical and readily available copper catalyst, constructing C-N bonds through propargyl substitution and aminolysis of the ester group to synthesize chiral quinoxalones. This method has advantages such as good substrate universality, high yield, good enantioselectivity, and ease of industrial production. The synthesis method of this invention does not require the use of special and expensive catalysts, and the reaction conditions are simple, requiring no special reaction environment such as high-pressure hydrogen, with low requirements for reaction equipment, making it easy to scale up for industrial production.

The invention discloses a quinoxaline compound as well as a preparation method, a pharmaceutical composition and application thereof, and relates to the technical field of pharmaceutical chemistry. In particular to a quinoxaline compound as shown in a formula I or pharmaceutically acceptable salt, prodrug, stereoisomer, diastereoisomer, enantiomer, tautomer, solvate, salt of solvate, polymorphic substance and isotope labeling compound of the quinoxaline compound. The quinoxaline compound designed and synthesized by the invention can effectively inhibit the activity of HIPK2 protein, the IC50 value of the preferable compound can reach the nanomolar concentration level, and the quinoxaline compound has better selectivity to HIPK1, achieves an excellent curative effect on the molecular level, and is very wide in application prospect; the preparation method of the compound provided by the invention is high in universality and suitable for expansion of various structure types.